Joan Albanell

19.5k citations
251 papers · 12.6k indexed · 5 hit papers · h-index 56
Topics
HER2/EGFR in Cancer Research (79 papers)Monoclonal and Polyclonal Antibodies Research (36 papers)Cancer Treatment and Pharmacology (33 papers)

In The Last Decade

Joan Albanell

245 papers receiving 12.3k citations

Hit Papers

Recombinant humanized anti-HER2 antibody (Herceptin) enha...199820262007201619982002200120092012250500750

Peers

Joan Albanell
Comparison fields: 5 of 135
  • Oncology 7.9k
  • Molecular Biology 4.8k
  • Cancer Research 3.0k
  • Pulmonary and Respiratory Medicine 2.9k
  • Radiology, Nuclear Medicine and Imaging 2.4k
Replace Federico Rojo with:
Federico Rojo Spain
Josef Rüschoff Germany
Joel Picus United States
Tim Meyer United Kingdom
Aleix Prat Spain
David M. Nanus United States
Luc Dirix Belgium
Shinichi Toyooka Japan
Nicola Normanno Italy
Daniel W. Visscher United States
Joan Albanell relative to Federico Rojo Spain Federico Rojo's profile →
Citations per field
00.5×1.5×
Federico Rojo · 1×
Citations per year

Countries citing papers authored by Joan Albanell

Since Specialization
Citations

This map shows the geographic impact of Joan Albanell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joan Albanell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joan Albanell more than expected).

Fields of papers citing papers by Joan Albanell

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joan Albanell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joan Albanell. The network helps show where Joan Albanell may publish in the future.

Co-authorship network of co-authors of Joan Albanell

This figure shows the co-authorship network connecting the top 25 collaborators of Joan Albanell. A scholar is included among the top collaborators of Joan Albanell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joan Albanell. Joan Albanell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 7
2 5
3 2
4 3
5 24
6 27
7 71
8 42
9 3
10 12
11 98
12 22
13 107
14 10
15 122
16 25
17
ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells.
213
18
NH(2)-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer.
177
19 195
20
Node-negative breast cancers with p53(-)/HER2-neu(-) status may identify women with very good prognosis.
40

About Joan Albanell

Joan Albanell is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine, having authored 251 papers that have together received 12.6k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (79 papers), Monoclonal and Polyclonal Antibodies Research (36 papers) and Cancer Treatment and Pharmacology (33 papers). The work is most often cited by research in Oncology (7.9k citations), Cancer Research (3.0k citations) and Radiology, Nuclear Medicine and Imaging (2.4k citations). Joan Albanell has collaborated with scholars based in Spain, United States and United Kingdom. Frequent co-authors include José Baselga, Federico Rojo, Ana Rovira, Joaquı́n Arribas, John Mendelsohn, Youngmee Kim, Jordi Codony‐Servat, Aňa Lluch, José Baselga and Larry Norton. Their work appears in journals such as Nature Medicine, Nature Communications and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026